News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,726 Results
Type
Article (40471)
Company Profile (264)
Press Release (671982)
Multimedia
Podcasts (71)
Webinars (17)
Section
Business (204520)
Career Advice (2017)
Deals (35485)
Drug Delivery (99)
Drug Development (81257)
Employer Resources (173)
FDA (16319)
Job Trends (14925)
News (345996)
Policy (32692)
Tag
Academia (2560)
Accelerated approval (15)
Adcomms (24)
Allergies (114)
Alliances (49590)
ALS (133)
Alzheimer's disease (1552)
Antibody-drug conjugate (ADC) (217)
Approvals (16414)
Artificial intelligence (391)
Autoimmune disease (66)
Automation (27)
Bankruptcy (361)
Best Places to Work (11641)
BIOSECURE Act (20)
Biosimilars (148)
Biotechnology (175)
Bladder cancer (128)
Brain cancer (45)
Breast cancer (483)
Cancer (3752)
Cardiovascular disease (297)
Career advice (1697)
Career pathing (33)
CAR-T (221)
CDC (42)
Cell therapy (594)
Cervical cancer (31)
Clinical research (68093)
Collaboration (1283)
Company closure (4)
Compensation (910)
Complete response letters (43)
COVID-19 (2678)
CRISPR (70)
C-suite (551)
Cystic fibrosis (128)
Data (4462)
Decentralized trials (2)
Denatured (22)
Depression (94)
Diabetes (416)
Diagnostics (6532)
Digital health (33)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (182)
Drug pricing (154)
Drug shortages (28)
Duchenne muscular dystrophy (191)
Earnings (88760)
Editorial (45)
Employer branding (21)
Employer resources (151)
Events (115279)
Executive appointments (922)
FDA (18708)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (1170)
Gene editing (155)
Generative AI (30)
Gene therapy (471)
GLP-1 (861)
Government (4599)
Grass and pollen (5)
Guidances (347)
Healthcare (18858)
HIV (42)
Huntington's disease (34)
IgA nephropathy (59)
Immunology and inflammation (201)
Immuno-oncology (16)
Indications (52)
Infectious disease (2898)
Inflammatory bowel disease (170)
Inflation Reduction Act (13)
Influenza (91)
Intellectual property (184)
Interviews (315)
IPO (16610)
IRA (48)
Job creations (3640)
Job search strategy (1426)
Kidney cancer (15)
Labor market (72)
Layoffs (532)
Leadership (27)
Legal (7937)
Liver cancer (85)
Longevity (11)
Lung cancer (540)
Lymphoma (259)
Machine learning (29)
Management (59)
Manufacturing (572)
MASH (130)
Medical device (13608)
Medtech (13631)
Mergers & acquisitions (19741)
Metabolic disorders (1022)
Multiple sclerosis (131)
NASH (16)
Neurodegenerative disease (195)
Neuropsychiatric disorders (49)
Neuroscience (2494)
NextGen: Class of 2025 (6522)
Non-profit (4493)
Now hiring (58)
Obesity (480)
Opinion (238)
Ovarian cancer (133)
Pain (149)
Pancreatic cancer (165)
Parkinson's disease (225)
Partnered (27)
Patents (399)
Patient recruitment (309)
Peanut (52)
People (58219)
Pharmaceutical (63)
Pharmacy benefit managers (23)
Phase I (21201)
Phase II (29979)
Phase III (22332)
Pipeline (2665)
Policy (242)
Postmarket research (2564)
Preclinical (9022)
Press Release (64)
Prostate cancer (189)
Psychedelics (42)
Radiopharmaceuticals (256)
Rare diseases (591)
Real estate (5939)
Recruiting (69)
Regulatory (23447)
Reports (51)
Research institute (2350)
Resumes & cover letters (351)
Rett syndrome (15)
RNA editing (12)
RSV (66)
Schizophrenia (123)
Series A (192)
Series B (147)
Service/supplier (11)
Sickle cell disease (74)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (34)
Startups (3601)
State (2)
Stomach cancer (14)
Supply chain (92)
Tariffs (79)
The Weekly (47)
Vaccines (901)
Venture capital (63)
Weight loss (309)
Women's health (54)
Worklife (17)
Date
Last 7 days (682)
Last 30 days (2358)
Last 365 days (30428)
2025 (24509)
2024 (35223)
2023 (40085)
2022 (51181)
2021 (55720)
2020 (54090)
2019 (46551)
2018 (35022)
2017 (32113)
2016 (31484)
2015 (37558)
2014 (31328)
2013 (26349)
2012 (28574)
2011 (29270)
2010 (27333)
Location
Africa (727)
Alabama (71)
Alaska (7)
Arizona (267)
Arkansas (13)
Asia (38652)
Australia (6314)
California (9145)
Canada (2815)
China (836)
Colorado (384)
Connecticut (392)
Delaware (254)
Europe (83254)
Florida (1365)
Georgia (296)
Hawaii (2)
Idaho (60)
Illinois (708)
India (45)
Indiana (436)
Iowa (18)
Japan (314)
Kansas (118)
Kentucky (33)
Louisiana (17)
Maine (68)
Maryland (1201)
Massachusetts (6679)
Michigan (280)
Minnesota (527)
Mississippi (4)
Missouri (109)
Montana (29)
Nebraska (25)
Nevada (103)
New Hampshire (71)
New Jersey (2515)
New Mexico (28)
New York (2485)
North Carolina (1246)
North Dakota (8)
Northern California (4239)
Ohio (278)
Oklahoma (20)
Oregon (36)
Pennsylvania (1926)
Puerto Rico (18)
Rhode Island (43)
South America (1100)
South Carolina (48)
South Dakota (1)
Southern California (3518)
Tennessee (146)
Texas (1413)
United States (33168)
Utah (270)
Virginia (220)
Washington D.C. (77)
Washington State (763)
West Virginia (4)
Wisconsin (78)
Wyoming (1)
712,726 Results for "avid bioservices inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Avid Bioservices Welcomes Kenneth Bilenberg as new CEO
September 16, 2025
·
3 min read
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
September 11, 2025
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Avidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle Strength
Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the first disease-modifying treatment for facioscapulohumeral muscular dystrophy—with an application in the second half of 2026.
June 9, 2025
·
2 min read
·
Dan Samorodnitsky
Biotech Beach
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
Avid Bioservices, Inc. announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers of business sustainability ratings.
May 23, 2024
·
2 min read
Biotech Beach
Avid Bioservices to Participate at Upcoming May 2024 Investor Conferences
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced that the company will participate at two upcoming investor conferences.
May 7, 2024
·
1 min read
Press Releases
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 16, 2025
·
5 min read
Press Releases
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger
February 6, 2025
·
6 min read
Biotech Beach
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization, announced the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029.
March 7, 2024
·
5 min read
Press Releases
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
July 1, 2024
·
1 min read
Press Releases
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
February 6, 2025
·
5 min read
1 of 71,273
Next
